‘Text/HTML’ of page ‘ NRG-LU003: Alk+ Lung Cancer’
Study Brochure
Read MoreContent Block Tag: NRG-LU003: Alk+ Lung Cancer
‘Text/HTML’ of page ‘ NRG-LU003: Alk+ Lung Cancer’
FAQs are no longer available for this page.
Read More‘Text/HTML’ of page ‘ NRG-LU003: Alk+ Lung Cancer’
About This Study NRG-LU003 was a National Cancer Institute and NRG Oncology clinical trial designed to study clinical benefit of a 2nd or 3rd generation ALK inhibitor, MET inhibitor, or chemotherapy in patients who developed cancer progression on a second-generation ALK inhibitor. Treatment was to be assigned based on genetic changes identified on their tumor […]
Read More